Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer

Authors

M. Catherine Pietanza, Weill Cornell Medical College
Saiama N. Waqar, Washington University School of Medicine in St. Louis
et al

Journal

Journal of Clinical Oncology

Publication Date

2018

Volume

36

Issue

23

First Page

2386

Last Page

2394

Document Type

Open Access Publication

DOI

10.1200/JCO.2018.77.7672

Rights and Permissions

Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018 Aug 10;36(23):2386-2394. doi: 10.1200/JCO.2018.77.7672. © 2018 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License.

Recommended Citation

Pietanza, M. Catherine; Waqar, Saiama N.; and et al, "Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer." Journal of Clinical Oncology. 36, 23. 2386 - 2394. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/8365